In August 2024, Eli Lilly & Company announced the positive outcomes of the SURMOUNT-1 trial, indicating that Tirzepatide (marketed as Zepbound and Mounjaro) decreased the risk of developing type 2 diabetes by 94% in individuals with prediabetes, obesity, or overweight
Key SleepOptimizing Peptides and Their Evidence CJC1295 (a longacting GHRH analog), Ipamorelin, Sermorelin, and Delta SleepInducing Peptide (DSIP) mechanisms CJC1295 (a longacting GHRH analog) and Ipamorelin synergistically stimulate pulsatile growthhormone (GH) release from the pituitary, deepening slowwave sleep without raising cortisol
Enzyme-linked immunosorbent assay (ELISA) kits for tumor necrosis factor-alpha (TNF-), interleukin-1 beta (IL-1), and interleukin-6 (IL-6) were sourced from Thermo Fisher Scientific Inc
Science 346 , 318322 (2014)